Zhejiang Int'l Group Co News
News
0
Ticker
000411.SZ
ISIN
CNE0000008D9
Zhejiang Int'l Group Co Eulerpool News
Zhejiang Int'l Group Co Stock News
Zhejiang Int'l Group Co is being monitored by journalists and investors worldwide. We gather the latest Zhejiang Int'l Group Co news here.
Zhejiang Int'l Group Co Stock Press Releases
Zhejiang Int'l Group Co regularly publishes news on the company's website that are relevant for investors.
Zhejiang Int'l Group Co News 2026
This page contains all current news, analysis and press releases for Zhejiang Int'l Group Co stock (000411.SZ, ISIN: CNE0000008D9). This includes Eulerpool news, company analysis and official press releases. Data is updated regularly to provide investors with a complete overview of the latest developments at Zhejiang Int'l Group Co.
Zhejiang Int'l Group Co Stock
Zhejiang Int'l Group Co Zhejiang Int'l Group Co., Ltd. generates revenue by wholesaling and retailing pharmaceuticals and medical devices. The company buys products from pharmaceutical manufacturers or suppliers and distributes them to distributors, medical institutions, and pharmacies. It also sells directly to consumers through retail terminals. The firm operates exclusively within Mainland China, serving a broad customer base across the healthcare sector. The business model relies on purchasing products from manufacturers or suppliers, then reselling them through wholesale channels to medical institutions and pharmacies, or via retail terminals to end consumers. This dual-channel approach allows the company to reach both institutional and individual customers without direct manufacturing involvement. Mainland China represents the sole market for all its operations. Zhejiang Int'l Group Co., Ltd. focuses on pharmaceutical and medical device distribution, targeting distributors, medical institutions, and pharmacies as key wholesale clients. Retail sales are directed toward consumers through its own retail terminals. The company does not engage in manufacturing, instead acting as a middleman between producers and end users within the Chinese healthcare market.